Stock market analyst Hitesh Chotalia has maintained 'sell' rating on Cipla Ltd stock with target of Rs 330.

According to analyst, the investors can sell the stock with stop loss of Rs 338.

Today, the stock opened at Rs 336.50 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 12.29 and 27.42 respectively.

The share price has seen a 52-week high of Rs 363 and a low of Rs 246.70 on BSE.

Pharma giant Cipla has made an investment of $65 million to get hold of a 40% and 25% stake in two biotech firms.

Cipla will purchase about 40% in an Indian biotechnology company and 25% in a Hong Kong based company.

The company has recorded a 40.41% increase in consolidated net profit, which stood at Rs 1,082.59 crore for the fiscal ended March 2010 as against Rs 771.02 crore during the last financial year.

Cipla announced a dividend of Rs 2 per share of Rs 2 face value for the fiscal 2009-10.

The company's total operating income for the period was Rs 5,624.91 crore as against Rs 5,246.07 crore during the last fiscal.